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Summary The distribution of iodine-131 (I31I) labelled antibody to carcinoembryonic antigen (CEA) has
been studied in 16 patients with colorectal cancer. Levels of tumour and normal tissue radioactivity were
measured by serial gamma-camera imaging and counting of blood and urine. Maximum concentrations were
found in tumour 8h after administration and varied up to 9-fold in different patients. Higher levels were
found on average in tumour than in any other tissue. Liver, lung and blood were the other tissues in which
antibody was concentrated relative to the rest of the body. Antibody cleared from all these tissues over 1 week.
Second antibody directed against the antitumour (first) antibody was given 24h after first antibody in order
to accelerate clearance from the blood. This increased the tumour to blood ratio but had little effect on other
tissues. Cumulative radiation dose to tumour and normal tissue was estimated. In patients with the most
efficient localisation the tumour to body ratio was 20:1 and tumour to blood ratio 5:1. This may be
sufficient for effective therapy of cancer in patients selected for efficient antibody localisation. The data may
be used to estimate the effect of different therapeutic strategies. For instance, in the time after second
antibody administration the average tumour to blood ratio of radiation dose was 11:1, suggesting that two
phase systems in which the therapeutic modality is given after a good tumour to normal tissue ratio is
obtained may be effective for the majority of patients.
Antibody targeted therapy of cancer requires that a favour-
able distribution of antibody is sustained in tumour relative
to normal tissues. Favourable distributions have been shown
in mice bearing xenografts of human tumours (Sharkey et
al., 1987; Buchegger et al., 1988; Begent et al., 1987) and an
antitumour effect is achieved in these systems (Goldenberg et
al., 1981; Sharkey et al., 1987; Zalcberg et al., 1984; Jones et
al., 1985; Buchegger et al., 1988; Lee et al., 1988;
Wakabayashi, 1984; Chiou et al., 1988; Badger et al., 1986;
Ceriani & Blank, 1988). Although responses are reported in
patients treated systemically with 131I-labelled antitumour
antibodies (Order et al., 1985; Lenhard et al., 1985;
Carrasquillo et al., 1984; Rosen et al., 1987; DeNardo et al.,
1988) these have not been sufficient for other forms of
therapy to be replaced. Understanding the reasons for this
depends on a knowledge of the time course of antibody
distribution in man which is lacking.
Gamma-camera imaging has given some serial measure-
ments of radioactivity in tissues of patients receiving 1311-
labelled antibody (Leichner et al., 1981; Hammond et al.,
1984; Carrasquillo et al., 1984). However, observations were
made at few time points and there were no data from the
first 24h when activity may be highest. The planar imaging
method used (Thomas et al., 1976) is reasonably accurate
when there are no overlying tissues with significant levels of
activity but is unsatisfactory for measuring activity in
tumours or other organs lying deep in the body.
This paper describes the use of a gamma-camera system to
assess antibody distribution in tumour and normal tissues
throughout the time course of therapy. Single photon emis-
sion tomography (SPET) (Riggs et al., 1988) was used to
give three-dimensional data for quantitation of radioactivity
where planar imaging was inadequate. Patients with colo-
rectal cancer were studied after receiving 1311 antibody to
CEA and cumulative radiation doses calculated. The effect
of second antibody to accelerate clearance of the antitumour
antibody from the blood (Begent et al., 1982, 1987) and the
effect of increasing the amount of antibody administered
were investigated.
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Methods
Antibodies
PK4S sheep anti-CEA antibody, affinity purified by elution
from a column of CEA bound to Sepharose, has been
described previously (Begent et al., 1986a, 1987).
Antibody was radiolabelled by the chloramine T method
over ice to a specific activity of 15.2-24mCimg-1 antibody
(median 19.4). After radiolabelling, reactivity of the antibody
was confirmed by reacting it with CEA on a nitrocellulose
disc. Binding was shown by autoradiography after washing
the disc. Horse anti-goat or donkey anti-sheep second anti-
body was prepared as described previously (Begent et al.,
1987) and 4.0-5.3 (median 4.8) times the amount of protein
of the first antibody was given. Antibodies were prepared in
accordance with the Operation Manual for Control of
Production, Preclinical Toxicology and Phase 1 Trials of
Antitumour Antibodies and Drug Antibody Conjugates
(1986).
Human anti-sheep and human anti-donkey antibody were
measured by enzyme immunoassay as described by
Ledermann et al. (1988) for human anti-mouse antibody.
Patients
Patients had unresectable local recurrent or metastatic carci-
noma of the colon or rectum. With ethical committee
approval and after obtaining signed written consent, the
following protocol was commenced.
Day -3 Potassium iodide 180mg t.d.s. p.o. and continued
for 31 days.
Day -1 Intradermal injection of 10pg anti-CEA antibody
and 10,ug second antibody to test for immediate type
hypersensitivity. Potassium perchlorate 2000mg q.d.f. for 5
days.
Day 0 1311 antibody in approximately 20ml in a lead
shielded vial was infused intravenously by displacement of
the contents of the vial by 250ml of 0.9% saline which was
run through the vial. The infusion was completed in 20min,
by which time less than 5% of the initial radioactivity was
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detectable in the vial. Three litres of saline 0.9% alternating
with dextrose 5% infused intravenously daily for 3 days to
ensure rapid clearance of 1311 from the urinary tract.
Day I One hour after oral administration of 600mg soluble
aspirin and 8mg chlorpheniramine, 10% of the second
antibody was given intravenously over 10min. If there was
no reaction after 20min, the remainder of the second
antibody was given over 20min.
Toxicity to patients was measured using WHO criteria
(WHO, 1979).
Estimation of tissue activity and cumulative radiation dose
Whole blood reactivity was measured with an LKB
Compugamma in samples taken 20min and 6h after 1311
antibody, immediately before and 2h after second antibody
and then on days 2, 3, 4, 6, 13 and 20. Whole body activity
was estimated by subtracting cumulative urine activity (LKB
Compugamma) from the administered activity.
Activity in other organs was determined by gamma-
camera imaging with the whole body scanning facility of the
IGE Gemini gamma-camera. A high resolution 400keV
collimator with a full width half maximum (FWHM) of
11.2mm at 100mm in air was used for most of the work. A
second 400keV collimator with a FWHM of 14.1 mm at
100mm in air and a sensitivity of 3 times that of the first
collimator was used for imaging at later times. Before
therapy an attenuation map of the patient was made with
the gamma-camera above the patient couch and a flood
source containing approximately 5mCi 1311 suspended from
the gamma-camera to hang beneath the patient and move
with the camera. Images were taken with and without the
patient in position so that attenuation of the whole body
could be mapped. Opposed views of the body were then
taken at approximately 6, 28, 54, 72, 144 and 216h after
antibody injection. The method of Thomas et al. (1976) was
used to estimate organ activities at these times. In some
patients serial tomographic studies were performed and
activities calculated as described by Riggs et al. (1988).
Activities in tumour lying behind other organs, such as the
bladder, were calculated in this way.
Clearance curves were calculated by fitting double expo-
nential curves to these serial estimates of blood and organ
activity. Cumulated dose was calculated from integration of
the clearance curves and estimates of tumour volume
obtained from X-ray computerised tomography scans.
Results
Four groups were studied: (1) five patients receiving 2.5mg
of antibody labelled with a mean of 51 mCi (range 38-60) of
1311 without second antibody; (2) five patients receiving
2.5mg of antibody labelled with a mean of 50mCi (range
40-60) with second antibody; (3) three patients receiving
5mg of antibody labelled with a mean of 89mCi (range 77-
100) with second antibody; and (4) three patients receiving
7.5mg of antibody labelled with a mean of 147mCi (range
143-152) with second antibody. All liver and lung activities
were estimated from planar imaging. Tumour activity was
derived from planar images in seven cases and the remainder
could only be measured by SPET because of overlying
normal tissues.
Distribution of antibody
The time course of activity in various tissues after correction
for physical decay of 131I gives an indication of antibody
distribution. Data for each of the four groups are given in
Table I. Because the times of imaging varied by a few hours
between patients, the values for each patient were plotted
and values for the same time point read off for each patient
for calculation of the mean values in Table I. The mean
activity in the body is shown and levels above this represent
relative concentration of antibody in the tissue concerned.
Antibody concentration is seen in tumour, blood, liver and
the lungs. The rest of the body had lower levels except for
the spleen which occasionally showed concentration as
detailed below. Activity was also seen in the urinary tract
but represents 131I separated from the antibody. No attempt
was made to quantitate activity in areas of low activity
where statistical error inherent in the low count rates would
compromise the validity of activity measurements.
Table I Mean per cent injected activity per kg (s.d.) for various tissues with time, values
corrected for physical decay
Hours Tumour Blood Liver Lung Body
No second antibody 2.5mg PK4S
8
24
48
72
144
10.4(11)
7.0(8.2)
3.7(3.2)
2.4(2.4)
1.3(1.2)
Second antibody 2.5mg PK4S
8 9.0(7.2)
24 5.7(4.6)
48 3.0(2.7)
72 1.7(1.4)
144 0.6(0.4)
Second antibody 5mg PK4S
8 7.9(5.1)
24 4.8(1.9)
48 2.8(0.7)
72 1.6(0.6)
144 0.5(0.4)
Second antibody 7.5mg PK4S
8 4.7(1.8)
24 3.0(0.4)
48 1.4(0.8)
72 0.9(0.5)
144 0.4(0.2)
6.0(1.7)
3.5(1.2)
1.7(0.8)
1.0(0.5)
0.4(0.3)
5.4(1.5)
2.9(1.3)
0.5(0.2)
0.2(0.1)
5.4(0.5)
3.7(0.7)
0.9(0.3)
0.6(0.2)
5.5(0.8)
2.4(1.4)
0.9(0.7)
0.3(0.2)
8.5(2.0)
6.1 (1.8)
3.8(1.9)
2.4(1.5)
1.2(0.9)
7.6(1.3)
5.4(1.3)
2.7(0.9)
1.7(0.7)
0.8(0.3)
8.4(2.9)
5.7(2.1)
3.4(1.9)
2.2(1.2)
0.8(0.4)
7.3(0.9)
4.8 (1.3)
2.3(1.2)
1.3(0.5)
0.6(0.1)
5.8(0.9)
4.4(1.3)
2.3(1.2)
1.1(0.1)
0.5(0.3)
6.3(1.5)
4.0(1.3)
1.7(0.9)
0.8(0.5)
0.4(0.1)
6.6(0.8)
4.8(0.7)
2.6(1.1)
1.5(0.9)
0.5(0.3)
8.4(0.1)
5.0(2.2)
2.1(1.6)
1.0(0.6)
0.3(0)
1.2(0.3)
0.9(0.2)
0.6(0.2)
0.5(0.2)
1.1(0.3)
0.8(0.3)
0.5(0.3)
0.4(0.2)
1.1(0.2)
0.9(0.1)
0.5(0.1)
0.4(0.1)
0.9(0.2)
1.0(0.4)
0.6(0.3)
0.2(0.2)408 R.H.J. BEGENT et al.
Blood activity
Activity in blood fell rapidly so that tumour and liver values
exceeded it by 8h (TableI). This may have resulted from
antibody uptake in these tissues. Second antibody acceler-
ated clearance from the blood, improving tumour to blood
ratios at all three levels of administered activity. Second
antibody produced a marked effect on blood within 2h as
shown in Figure 1. Antibody-bound 1311, estimated by
measuring the proportion of counts precipitated by addition
of an equal volume of 20% trichloracetic acid, was 72.6%
(standard deviation 19.4) 66-72h after injection in the five
patients in whom it was studied.
Tumour activity
This was on average higher than any other tissue although
considerable variation occurred between patients, as indi-
cated by the high standard deviations. Activity in tumour
was highest 8h after antibody administration and fell at a
rate similar to other tissues with high activity (Table I). An
example of the best localisation without second antibody is
shown in Figure 2a. A gamma-camera image of this tumour
is shown in Figure 2b. The best localisation seen with second
antibody is shown in Figure 3.
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Liver and lung activity
This antibody localises to liver in areas which appeared to be
tumour-free and to a lesser extent in lung (Table I). The
activity did not fall after second antibody indicating that the
effect was not caused by blood located in the liver vascula-
ture. No rise was seen in liver activity after second antibody
administration (Table I).
Cumulative radiation dose
Mean beta doses to various tissues derived from the data in
Table I without decay correction are shown in Table II.
Without second antibody the tumour to blood dose ratio
was 1.8:1 but ratios were less favourable for liver, lung arnd
spleen. The tumour to whole body ratio of 4.5:1 reflected
lower activity in most other parts of the body. The use of
second antibody reduced the dose to blood though the
difference did not reach statistical significance. The tumour
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Figure 2 a, Radioactivity in tumour and normal tissues after
injection of 2.5mg 1311 antibody in a patient not receiving
second antibody. b, Anterior gamma-camera image showing
concentration of radioactivity in liver deposits (arrowed) of colon
carcinoma in the same patient at 213h.
to blood ratio increased to 2.5:1 but there was a small
reduction in tumour dose. Clearance of 131I through the
liver by second antibody did not increase the dose to this
organ. Doses to the spleen recorded by planar imaging were
higher than other organs. SPET gave much lower values
(Table III) and these were probably more accurate because
planar imaging does not permit separation of radioactivity in
the spleen from that in the overlying left lobe of liver and
20 -
U)
U)
03)
0)
._ Cu
._
4- 0
m
o-0
10 20 30 40 50 60 70 80
Hours
Flgure 1 Whole blood radioactivity (mean +±s.d.) as a percent-
age of activity 20min after the start of 1311 antibody infusion.
Five patients not receiving second antibody are compared with
five who received second antibody at 24h.
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Figure 3 Radioactivity in tumour and normal tissues after
injection of 2.5mg 131I antibody in a patient receiving second
antibody.
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Table II Cumulative radiation dose (cGymCi-1 administered):
mean, s.d. and range
Tumour Blood Liver Lung Body
No second antibody
51 mCi 2.0 1.0 1.8 1.1 0.4 mean
(1.8) (0.3) (1.0) (0.3) (0.2) s.d.
0.5-5.1 0.4-1.4 1.2-3.6 0.9-1.4 0.2-0.7 range
Second antibody
50mCi 1.5 0.6 1.5 0.9 0.3
(1.2) (0.2) (0.3) (0.3) (0.1)
0.7-3.7 0.4-0.8 1.2-1.9 0.7-1.3 0.1-0.5
89mCi 1.2 0.7 1.6 1.2 0.3
(0.5) (0.1) (0.6) (0.3) (0.1)
0.7-1.7 0.7-0.8 1.1-2.3 0.9-1.5 0.2-0.4
147mCi 0.8 0.7 1.2 1.1 0.3
(0.3) (0.1) (0.4) (0.5) (0.1)
0.5-1.0 0.6-0.8 0.9-1.6 0.8-1.6 0.2-0.3
Amounts in mCi refer to the mean administered activity for each
group.
Table III Comparison of planar and SPET doses
Spleen Liver
(3 patients) (5 patients)
SPET Planar SPET Planar
Dose(cGYmCi1) 0.8 4.1 0.9 1.5
Standard deviation 0.2 2.2 0.1 0.5
stomach. Table III also shows a comparison of SPET and
planar imaging for measurement of liver dose. As before the
doses for SPET are lower but showing much smaller differ-
ences than the spleen because there are fewer overlying
tissues in the regions chosen for assessment. Escalating the
administered activity had little effect on dose per mCi
injected. Although tumour doses appeared to fall, the differ-
ences were not statistically significant and SPET tumour
doses per mCi injected, which are probably more accurate,
showed no trend to fall with increasing administered activity
in nine patients studied in this way.
Effect of second antibody
Although overall doses were not significantly reduced by
second antibody, the part of the dose delivered to the blood
more than 48h after anti-CEA antibody administration (24h
after second antibody) is less with second antibody than
Table IV Mean dose after 48h (cGymCi- 1)
Blood (s.d.) Tumour Tumour:blood
No second antibody 0.31 (0.17) 0.75(0.8) 3.0(3.3)
Second antibody 0.06 (0.03) 0.54(0.4) 11.1(8.0)
Five patients in each group receiving 2.5mg antibody.
Mean tunrur:blood ratio is derived from individual ratios.
without (significant at the 5% level by the Mann-Whitney U
test). The result is a usefully improved mean tumour to
blood ratio of 11:1 as shown in Table IV.
Toxicity
The toxicity recorded in 11 patients receiving second anti-
body at various levels of administered activity together with
five control patients not receiving second antibody only is
shown in Table V. Haematological toxicity was the only
effect related to administered activity seen. Rigors occurred
in some patients and this was eliminated after a change in
chromatography equipment near the end of the study. There
was no liver or lung toxicity although these organs received
doses as high as or higher than blood through which marrow
dose is thought to be given. This suggests that marrow is
more radiosensitive than the other organs.
Response
The patient with the most favourable radiation dose to
tumour (Figure 2) had a partial response of a liver metastasis
as shown in Figure 4. One patient had a fall of serum CEA
to less than 50% of pretreatment values but this may be
attributable to clearance of circulating CEA by administered
antibody. CA 19/9 levels were elevated in seven patients
before therapy and none showed a fall. One additional
patient not included in the dosimetry study had a progressive
fall from 38 to 14 units at 18 days associated with pain relief
and subsequent rising values associated with a return of
symptoms.
Human anti-sheep and anti-donkey antibody
Eight of the 16 patients developed human IgG anti-sheep
antibodies after treatment. A sample was considered positive
if the IgG anti-sheep antibody value of a post-treatment
sample was either more than twice the pretreatment
measurement in patients with pretreatment values
>5ygml-
I or, the post-therapy value was >10Mgml -1 in
patients whose pretreatment samples were <6pgml-1. Peak
values were recorded from 10 to 29 days. Human anti-
donkey antibody developed after treatment in eight of the 11
patients receiving second antibody and in none of those not
given second antibody.
Discussion
Quantitative measurements of the distribution of an anti-
tumour antibody have been made in relation to time.
Although the data were from patients having radionuclide
therapy the information is likely to be relevant to other
forms of antibody targeted therapy. The data were derived
from direct measurement of blood and urine and from
planar and three-dimensional (SPET) gamma-camera imag-
ing. The latter is essential for estimation of levels of activity
in tumours which lie deep in the body and have overlying
normal tissues tissues containing significant amounts of
radioactivity. Such quantitation from SPET images is only
Table V Toxicity in relation to treatment regimen
Toxicity
Mg offirst" Second No. of (no. ofpts x WHO grade)
antibody mCi antibody patients Hb WBC Plat N/V Rigor
2.5 38-60 No 5 1 x l I xI 0 1 x2 2x2
2.5 40-60 Yes 5 0 0 0 0 4x 2
5 77-100 Yes 3 0 0 0 0 1x2
7.5 143-152 Yes 3 0 0 1 x3 1 x2 2x2
1 x3
Hb, haemoglobin (gdl-1); WBC, total white blood cell count (x 1091-1); plat, platelets (x 1091-1);
N/V, nausea or vomiting.410 R.H.J. BEGENT et al.
Figure 4 Computerised tomography of the liver before (a) and
34 days after (b) treatment, showing a reduction in size of the
tumour deposit (arrowed).
accurate because of the count rate with therapeutic amounts
of administered activity of 131I (Riggs et al., 1988).
Although measurement of 1311 levels is not an absolute
indication of antibody localisation because of de-iodination
of antibody, it gives the best representation available for
clinical studies. Indium-111-labelled antibodies, for example,
lead to prolonged retention of radionuclide in normal liver
and bone.
The finding of higher levels of activity in the tumour than
blood or other normal tissues as soon as 8h after administ-
ration was associated with progressive clearance from blood
and tumour over the next 6 days. This pattern differs from
that of the same antibody in nude mice bearing human colon
carcinoma xenografts. The animals showed slower blood
clearance and the antibody continued to accumulate in
tumours for 2 days or more (Begent et al., 1987). The
concentration of antibody in the tumour only exceeded that
in blood after 8 days. The more rapid blood clearance of
antibody in man would tend to give an earlier peak uptake
of antibody in tumour. This is consistent with the findings
with F(ab')2 fragments of antibody in animals which are
cleared rapidly from the circulation. The tumour to blood
ratios are high at early times and antibody then clears from
the tumour (Harwood et al., 1987). Second antibody is
thought to clear first antibody through the liver but an
increase in liver activity was not seen after second antibody
administration. This is probably because 1311 antibody had
been cleared from the liver by the time of gamma-camera
imaging 5-6h after second antibody administration.
The variation in tumour uptake between individuals was
striking, the highest having 9.6 times the concentration of the
lowest at 8h. This- variability is also expressed in the high
standard deviations of tumour activities compared with the
more reproducible distribution in normal tissues. For indivi-
dual patients, however, tumour activity followed a predict-
able decline with time suggesting that the variation is the
result of different characteristics of different tumours rather
than inaccuracies in measurement of activity by the gamma-
camera. This is supported by the validation of the SPET
method used for tumour activity measurement (Riggs et al.,
1988). Other studies have shown considerable variation in
the uptake of antibodies in tumour (Mach et al., 1980;
Leichner et al., 1984; Begent et al., 1986a; Estaban et al.,
1987). This is therefore likely to be of major importance in
selection of patients for antibody therapy. A method of
quantitating tumour localisation of antibody is likely to be
needed for selection of individual patients for any form of
antibody targeted therapy.
Applying these data about antibody distribution to the
example of therapy with the beta emission of 1311, measure-
ments of cumulative radiation dose to tumour and normal
tissues can be made to assess the possibilities for effective
therapy. The patient with the highest tumour activity had a
beta radiation dose to tumour of 5.1 cGymCi-1 injected
with a whole body dose of 0.25 cGymCi-1, a ratio of
20.4:1. Dykes et al. (1987) have predicted that a ratio of
30:1 is needed for effective therapy assuming that a whole
body dose of 200cGy is tolerable. By these criteria effective
therapy may be in range for some patients, particularly with
repeated antibody administration as is now possible by use
of cyclosporin A to prevent the human anti-antibody
response (Ledermann et al., 1988). For the majority,
however, effective therapy would not appear practical with
this antibody.
The model of Dykes et al. (1987), on which the assump-
tions above are based, does omit factors which are worthy of
consideration. Bone marrow radiation dose is probably more
relevant than whole body dose as the factor limiting ad-
ministered activity. This would be in keeping with data from
whole body irradiation by an external beam and from
therapy with 1311 antibody (Carrasquillo et al., 1984;
Leichner, 1981). The data of Benua et al. (1962) for 131I
therapy of thyroid cancer indicate that a radiation dose to
blood of 200cGy will produce myelosuppression from which
recovery is predictable.
It is evident that tumour to blood ratios are less favour-
able than those for tumour to body. Using the mean tumour
and blood radiation doses for patients without second
antibody from Table II, a tumour dose of 360cGy would be
given for a blood dose of 200 cGy. The best patient,
however, would receive a tumour dose of 1,020cGy. With
second antibody the mean tumour dose would be 500cGy
and the best 1,345 cGy. Responses of cutaneous T-cell
lymphoma and B-cell lymphoma have been reported with
131I-labelled antibody therapy delivering a tumour dose
estimated between 500 and 100 cGy (Rosen et al., 1987;
DeNardo et al., 1988). Lymphoma is more radiosensitive
than colorectal cancer but it is interesting that the patient in
the present study with the highest radiation dose to tumour
of 306cGy had a short-lived partial response (Figure 4).
These responses are perhaps better than might be expected
with external beam radiotherapy and may be the result of an
underestimate of dose delivered to cancer cell nuclei. The
microscopic distribution of antibody within the tumour mass
favours localisation on and around tumour cells relative to
stromal and necrotic areas of tumour as discussed previously
(Begent et al., 1986b). The extent of the advantage produced
by this factor is unknown but if it is 5-fold a possibly
tumoricidal dose of 6.725 cGy could be delivered with a
single therapy to the patient with the most favourable
distribution if the administered activity was, increased until
the blood received 400 cGy. This factor may vary with
different tumour types; the extensive stromal and mucinous
areas common in colon carcinoma will separate cells to
which antibody may bind specifically giving a lower ap-
parent concentration of antibody than in a tumour of tightly
packed tumour cells such as hepatoma. This may explain the
apparently higher tumour doses achieved by Order et al.
(1985) in hepatoma.
A higher bone marrow dose might be acceptable with
appropriate facilities to support a myelosuppressed patient.ANTIBODY DISTRIBUTION AND DOSIMETRY 411
It is likely that recovery would be usual with 400cGy to
bone marrow and that higher doses would be tolerable with
autologous bone marrow transplantation.
In humans the maximum administered activity will then
depend on the tolerance of other normal tissues. In the
example shown here the liver receives the highest dose of any
normal tissue followed by the lung. It is interesting that liver
and lung were the tissues in which the greatest flux of
antibody was predicted by the model of Covell et al. (1986).
These organs would probably be damaged with sufficient
escalation of administered activity. The failure to find any
hepatic toxicity may be because of lower intrinsic radio-
sensitivity in the liver than the bone marrow. The antibodies
did not react with normal human liver by immunohisto-
chemistry which does not suggest a specific reaction with an
antigen on normal liver cells. Clearance of immune com-
plexes formed between antibody and circulating CEA via the
liver is a further possibility.
The purpose of giving second antibody was to investigate
whether the radiation dose to bone marrow could be reduced
permitting a higher tumour dose to be given. Although
blood activity was significantly reduced after second anti-
body administration, this had only a small effect on the
cumulative radiation dose, most of which had already been
given before second antibody administration. Activity was
reduced less in the tumour than in blood after second
antibody and this raises the possibility that the favourable
tumour to blood ratio after this could be exploited. The
mean ratio of cumulative radiation dose after second anti-
body was 11:1, which offers a favourable therapeutic ratio
for the majority of patients. This could be exploited by two
phase systems in which the therapeutic agent is given after
the antitumour antibody and localises to antibody already
on the tumour (Raso, 1982) or is activated at the tumour
site by an enzyme linked to antibody (Bagshawe et al., 1988).
Measurements of antibody distribution over a period of
time after administration identify the favourable and
unfavourable features of antibody therapy. The influence of
modifications such as escalation of administered activity and
the use of second antibody can be quantitated. Although the
methods for dosimetry are laborious the results enable work
to be directed to overcoming the problems and exploiting the
opportunities which have been identified.
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